Literature DB >> 24947916

Always on guard: test of high vs. low control conditions in obsessive-compulsive disorder patients.

Eyal Kalanthroff1, Gideon E Anholt2, Avishai Henik3.   

Abstract

Obsessive-compulsive disorder (OCD) is a relatively common psychiatric disorder characterized by recurrent obsessive thoughts and/or compulsive behaviors. It has been shown that OCD patients suffer from deficits in executive control. During Stroop task performance, it was found that cognitive control in healthy participants adjusts adaptively - control is reduced when conflict is less likely. Twenty-four individuals meeting criteria for OCD and 27 controls carried out two blocks of a Stroop task; one with high control (a third of the trials were neutral) and one with low control (75% of the trials were neutral). In the healthy control group, results replicated previous findings showing increased interference and decreased facilitation in the low control condition compared to the high control condition. OCD participants, on the other hand, showed no difference in results between the two blocks. Moreover, in the high control condition, interference was larger and facilitation was smaller compared to healthy controls, indicating less efficient executive control for both the informational and task conflict. We concluded that healthy controls adjust the level of control to changing circumstances whereas OCD patients have difficulties to adaptively make such adjustments. Implications for this novel evidence of deficient executive control of flexibility in OCD patients are discussed.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive control; Flexibility; OCD; Response inhibition; Stroop

Mesh:

Year:  2014        PMID: 24947916     DOI: 10.1016/j.psychres.2014.05.050

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  The effects of awareness and secondary task demands on Stroop performance in the pre-cued lists paradigm.

Authors:  Julie M Bugg; Nathaniel T Diede
Journal:  Acta Psychol (Amst)       Date:  2017-01-04

2.  Stroop proactive control and task conflict are modulated by concurrent working memory load.

Authors:  Eyal Kalanthroff; Amir Avnit; Avishai Henik; Eddy J Davelaar; Marius Usher
Journal:  Psychon Bull Rev       Date:  2015-06

3.  The Role of Response Inhibition in Medicated and Unmedicated Obsessive-Compulsive Disorder Patients: Evidence from the Stop-Signal Task.

Authors:  Eyal Kalanthroff; Tobias Teichert; Michael G Wheaton; Marcia B Kimeldorf; Omer Linkovski; Susanne E Ahmari; Abby J Fyer; Franklin R Schneier; Gideon E Anholt; H Blair Simpson
Journal:  Depress Anxiety       Date:  2016-03-17       Impact factor: 6.505

4.  Evidence for trial-by-trial dynamic adjustment of task control in unmedicated adults with OCD.

Authors:  Eyal Kalanthroff; Rachel Marsh; Ran R Hassin; Helen Blair Simpson
Journal:  Behav Res Ther       Date:  2020-01-25

5.  Executive Dysfunction in Obsessive-Compulsive Disorder and Anterior Cingulate-Based Resting State Functional Connectivity.

Authors:  Je-Yeon Yun; Joon Hwan Jang; Wi Hoon Jung; Na Young Shin; Sung Nyun Kim; Jae Yeon Hwang; Jun Soo Kwon
Journal:  Psychiatry Investig       Date:  2017-05-16       Impact factor: 2.505

6.  Negative Mood and Obsessive-Compulsive Related Clinical Constructs: An Examination of Underlying Factors.

Authors:  Gary I Britton; Graham C L Davey
Journal:  Front Psychol       Date:  2017-09-14

7.  Paradoxical response inhibition advantages in adolescent obsessive compulsive disorder result from the interplay of automatic and controlled processes.

Authors:  Nicole Wolff; Witold Chmielewski; Judith Buse; Veit Roessner; Christian Beste
Journal:  Neuroimage Clin       Date:  2019-06-08       Impact factor: 4.881

8.  Stopping at a red light: Recruitment of inhibitory control by environmental cues.

Authors:  Shachar Hochman; Avishai Henik; Eyal Kalanthroff
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.